Drug Approval | December 14, 2024
Acoramidis receives positive CHMP opinion for treatment of transthyretin amyloid cardiomyopathy
Final decision from the European Commission is anticipated within the coming months
Final decision from the European Commission is anticipated within the coming months
The trademark rights for these brands will be transferred to Lupin by March next year.
Zefylti will be available as 30 MU/0.5 mL and 48 MU/0.5 mL and is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
The CDMO business will be structured into three new business platforms designed to create a unified organization: Integrated Biologics, Advanced Synthesis, and Specialized Modalities
This product is indicated in coagulation disorders caused by vitamin K deficiency or interference with vitamin K activity.
Brenntag Specialties Pharma marks a strategic milestone with its first collaboration with a contract manufacturer to enhance its nutraceutical value chain
Acquisition adds potential best-in-class disease-modifying therapy for Alzheimer's disease
The successful completion of RRA assessment by the USFDA, would enable company to open up its business in the USA market
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
Subscribe To Our Newsletter & Stay Updated
